BRECKSVILLE, Ohio, May 7, 2025 /PRNewswire/ — Applied Medical Technology, Inc. proudly announces the launch of two cutting-edge suture passing solutions engineered for precision, efficiency, and adaptability in minimally invasive procedures: RHAPSO™ and GEMINI®.
RHAPSO™ – Versatile Suture Passing Instrument
Designed for surgeons seeking refined control and ease in suturing, RHAPSO™ is a 17-gauge fine needle suture passer that delivers exceptional performance in confined surgical spaces. Featuring a wide opening for enhanced suture capture, RHAPSO™ streamlines suturing through its spring-assisted, atraumatic grasper arms.
Key Benefits:
GEMINI® – Suture Passer with Magnet Technology
Introducing the next evolution in suture management, GEMINI® incorporates self-aligning magnet technology to simplify intracorporeal suture retrieval. Designed to minimize tissue trauma, GEMINI® includes magnetic suture loops and a magnetized grasper arm for seamless, reliable connection.
Key Benefits:
“With RHAPSO™ and GEMINI®, we’re equipping surgeons with tools that simplify complex tasks and support better patient outcomes,” said Joe Harr, Surgical Sales Manager at Applied Medical Technology, Inc. “These devices reflect our commitment to advancing surgical precision and procedural confidence.”
For ordering information, visit www.AppliedMedical.net or contact Customer Service at 800-869-7382.
About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use.
SOURCE Applied Medical Technology, Inc.
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…